Janone technologies announces registered direct offering priced at-the-market under nasdaq rules

Las vegas , aug. 18, 2023 /prnewswire/ -- janone (nasdaq: jan) (the "company"), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 899,348 shares of the company's common stock (or prefunded warrants in lieu thereof) at a purchase price of $0.8811 per share of common stock (or prefunded warrant) in a registered direct offering priced at-the-market under nasdaq rules. in addition, in a concurrent private placement, the company will issue unregistered warrants to purchase 899,348 shares of common stock at an exercise price of $0.7561 per share.
JAN Ratings Summary
JAN Quant Ranking